Methods of diagnosing inflammatory bowel disease through RNASET2
Described herein are methods of diagnosing inflammatory bowel disease, including but not limited to Crohn's Disease (CD), Ulcerative Colitis (UC), and/or Medically Refractive Ulcerative Colitis (MR-UC), using RNA-SET2, TL1A and/or IFN-Y. The methods may comprise treating inflammatory bowel disease by administering a therapeutically effective amount of a therapeutic agent to a subject. Described further herein are processes for patient identification and/or stratification.
1. A method of treating Inflammatory Bowel Disease (IBD) in a subject, the method comprising administering a therapeutically effective amount of a therapeutic agent to the subject, provided a single nucleotide polymorphism (SNP) at rs2149092 comprising a “T” at a nucleoposition 501 within SEQ ID NO: 2 is detected in a sample obtained from the subject.
2. The method of claim 1 , provided a SNP at rs1819333 comprising an “A” allele at a nucleoposition 501 within SEQ ID NO: 1 is detected in the sample obtained from the subject.
3. The method of claim 1 , wherein the IBD is severe IBD characterized by at least one of a therapeutic failure of an anti-Tumor Necrosis Factor alpha (TNFa) therapy, multiple flare-ups per year, stricturing disease, penetrating disease, and stricturing and penetrating disease.
4. The method of claim 1 , provided a SNP at rs9355610 is detected in the sample obtained from the subject.
5. The method of claim 4 , wherein the SNP at rs9355610 comprises a “G” allele at nucleoposition 501 within SEQ ID NO: 3.
6. The method of claim 1 , provided a SNP at rs6478109 or a SNP at rs7848647, or a combination thereof, is detected in the sample obtained from the subject.
7. The method of claim 1 , wherein the therapeutic agent comprises an anti-Tumor Necrosis Factor Ligand 1 (TL1A) antibody.
8. The method of claim 1 , wherein the IBD is Crohn's disease (CD), ulcerative colitis (UC), medically refractory UC (mrUC), or a combination thereof.
9. A method of diagnosing and treating inflammatory bowel disease in a subject, the method comprising:
a) subjecting a sample obtained from the subject to an assay adapted to determine a presence or an absence of a genotype comprising a single nucleotide polymorphism (SNP) rs2149092 comprising a “T” at a nucleoposition 501 within SEQ ID NO: 2;
b) detecting the presence or the absence of the genotype;
c) diagnosing inflammatory bowel disease (IBD) in the subject when the presence of the genotype is detected in step (b); and
d) treating the IBD in the subject diagnosed in (c) by administering an effective amount of a therapeutic agent to the subject.
10. The method of claim 9 , wherein the genotype further comprises a SNP at rs1819333 comprising an “A” allele at a nucleoposition 501 within SEQ ID NO: 1.
11. The method of claim 9 , wherein the IBD is severe IBD characterized by at least one of a therapeutic failure of an anti-Tumor Necrosis Factor alpha (TNFa) therapy, multiple flare-ups per year, stricturing disease, penetrating disease, and stricturing and penetrating disease.
12. The method of claim 9 , provided the genotype further comprises a SNP at rs9355610 comprising a “G” allele at nucleoposition 501 within SEQ ID NO: 3.
13. The method of claim 9 , wherein the assay comprises a genotyping assay selected from the group consisting of quantitative polymerase chain reaction (qPCR), a single nucleotide polymorphism (SNP) array, and sequencing.
14. The method of claim 9 , provided the genotype further comprises at least one of a SNP at rs6478109 and a SNP at rs7848647.
15. The method of claim 9 , wherein the therapeutic agent comprises an anti-Tumor Necrosis Factor Ligand 1 (TL1A) antibody.
16. The method of claim 9 , wherein the IBD is Crohn's disease, ulcerative colitis (UC), medically refractory UC, or a combination thereof.
17. The method of claim 15 , wherein the anti-TL1A antibody comprises a neutralizing TL1A antibody.
18. The method of claim 7 , wherein the anti-TL1A antibody comprises a neutralizing TL1A antibody.